NME output lifts from 20 year low
Thomson Scientific
September 2006
New research findings from The Centre for Medicines Research (CMR) International Ltd, a Thomson business, reveal that new molecular entity (NME) output rose in 2004 after a dramatic ten year decline. R&D expenditure and pharmaceutical sales both showed a steady increase over the same period, with sales outperforming R&D expenditure in recent years.
CMR International is the world's most authoritative source of pharmaceutical R&D performance management metrics and trend data. It works with all major pharmaceutical companies worldwide to gain unique insights through analysis of confidential, primary-source data. This exclusive research informs much of the world's publicly quoted pharmaceutical R&D statistics.
CMR's research has revealed a recent rise in NME output after a ten year decline (see figure 1). R&D expenditure and pharmaceutical sales both showed a steady increase o ver the same period. Sales has outperformed R&D expenditure in recent years, reflecting activities in emerging markets and the drive to find new indications for existing compounds.
This is just one example of the research trends illustrated in the CMR International Pharmaceutical 2006/2007 R&D factbook. The Factbook condenses the latest insights from CMR's uniquely comprehensive and robust industry-wide databases, with commentary that is available from no other provider. Each finding is presented in a clear, easily-understood chart, accompanied by a succinct commentary highlighting the key message together with an explanation of the methodology used and the definitions applied.
The Factbook is an indispensable reference and business planning tool used by decision makers in R&D, corporate finance, business strategy, marketing planning and corporate communications. They use the Factbook to inform their research, presentations and decision making, f inding answers to strategic questions such as:
- what are the trends in R&D expenditure, development time, and pipeline size?
- what are the clinical study trends in patient enrolment durations?
- where are clinical studies being conducted?
- what is the impact of therapeutic area when assessing the probability of success to market for one active substance from each of the key R&D stages?
Ordering and using the CMR International Pharmaceutical 2006/2007 R&D factbook
Additional information
Was this article useful?
Note for journalists
Looking for an expert source for your story?
Visit our Expert Directory